FdaApplication
NDA 204042
Identifiers
- fda_app_no: NDA204042
Properties
| Property | Value |
|---|---|
| applicant_name | JANSSEN PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2013-03-29 |
Revenue by product
INVOKANA
| Period | Revenue |
|---|---|
| Q4 2022 | $91.0M* |
| Q3 2022 | $109.0M* |
| Q2 2022 | $120.0M* |
| Q1 2022 | $128.0M* |
| Q4 2021 | $120.0M* |
| Q3 2021 | $133.0M* |
| Q2 2021 | $160.0M* |
| Q1 2021 | $150.0M* |
| Q4 2020 | $217.0M* |
| Q3 2020 | $224.0M* |
| Q2 2020 | $179.0M* |
| Q1 2020 | $175.0M* |
| Q4 2019 | $177.0M* |
| Q3 2019 | $179.0M* |
| Q2 2019 | $177.0M* |
| Q1 2019 | $202.0M* |
| Q4 2018 | $228.0M* |
| Q3 2018 | $190.0M* |
| Q2 2018 | $215.0M* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| INVOKANA | CANAGLIFLOZIN | 300MG | TABLET;ORAL |
| INVOKANA | CANAGLIFLOZIN | 100MG | TABLET;ORAL |
2 products